|Bid||44.75 x 0|
|Ask||47.78 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||19.93|
|Forward Dividend & Yield||1.27 (2.79%)|
|Ex-Dividend Date||May 14, 2021|
|1y Target Est||N/A|
Amgen (NASDAQ: AMGN) and Teneobio today announced an agreement under which Amgen will acquire Teneobio, a privately held, clinical stage biotechnology company developing a new class of biologics called Human Heavy-Chain Antibodies. Under the terms of the agreement, Amgen will acquire all outstanding shares of Teneobio at closing in exchange for a $900 million upfront cash payment, as well as future contingent milestone payments to Teneobio equity holders potentially worth up to an additional $1.
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.